Peringatan Keamanan

In acute toxicity studies with mice and rabbits, a dose of 20 ?g/kg of synthetic human secretin was not lethal with no clinical symptoms of toxicity. The no-observed-effect level (NOEL) in rats was 10 ?g/kg/day in a 14-day intravenous toxicity study without any evidence of adverse toxicity. The NOEL was 5 ?g/kg/day in dogs L1875.

Studies assessing the carcinogenic potential, mutagenicity, or potential for impairment of fertility have not been conducted with synthetic human secretin FDA Label.

Secretin human

DB09532

biotech approved

Deskripsi

Human secretin is a gastrointestinal peptide hormone that regulates secretions in the stomach, pancreas, and liver. The hormone is produced from the enterochromaffin cells in the duodenum in response to the duodenal content with the pH less than 4.5 L1875. The main action of secretin is to stimulate the pancreas to secrete pancreatic juice for pH regulation in the small intestines. Secretin is also responsible in body fluid homeostasis A32276 and bile production. Although it is a gastrointestinal hormone, secretin is also considered as a neuropeptide hormone since it is also expressed in the central nervous system A32275.

Purified synthetic human secretin, also referred to as RG1068, is available as an intravenous injection under the market name ChiRhoStim ® in the U.S.. It contains an amino acid sequence identical to the naturally occurring hormone consisting of 27 amino acids FDA Label that supports ?-helical formation A32275. The carboxyl-terminal amino acid, valine, is amidated. Synthetic human secretin displays equivalent biological activity and properties as naturally-occurring secretin A32265. It is indicated for the stimulation of the pancreatic and gastric secretions to aid in the diagnosis of pancreatic exocrine dysfunction and the diagnosis of gastrinoma, and facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP).

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The elimination half life of synthetic human secretin is 45 minutes [FDA Label].
Volume Distribusi The volume of distribution is 2.7 L [FDA Label].
Klirens (Clearance) The clearance of synthetic human secretin is 580.9 ± 51.3 mL/min [FDA Label].

Absorpsi

Following intravenous bolus administration of 0.4 mcg/kg, synthetic human secretin concentration rapidly declines to baseline secretin levels within 90 to 120 minutes FDA Label.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

163 Data
Tramadol The therapeutic efficacy of Secretin human can be decreased when used in combination with Tramadol.
Trospium The therapeutic efficacy of Secretin human can be decreased when used in combination with Trospium.
Oxyphenonium The therapeutic efficacy of Secretin human can be decreased when used in combination with Oxyphenonium.
Butabarbital The therapeutic efficacy of Secretin human can be decreased when used in combination with Butabarbital.
Butalbital The therapeutic efficacy of Secretin human can be decreased when used in combination with Butalbital.
Benzatropine The therapeutic efficacy of Secretin human can be decreased when used in combination with Benzatropine.
Ziprasidone The therapeutic efficacy of Secretin human can be decreased when used in combination with Ziprasidone.
Disopyramide The therapeutic efficacy of Secretin human can be decreased when used in combination with Disopyramide.
Talbutal The therapeutic efficacy of Secretin human can be decreased when used in combination with Talbutal.
Pentobarbital The therapeutic efficacy of Secretin human can be decreased when used in combination with Pentobarbital.
Amitriptyline The therapeutic efficacy of Secretin human can be decreased when used in combination with Amitriptyline.
Ipratropium The therapeutic efficacy of Secretin human can be decreased when used in combination with Ipratropium.
Methadone The therapeutic efficacy of Secretin human can be decreased when used in combination with Methadone.
Olanzapine The therapeutic efficacy of Secretin human can be decreased when used in combination with Olanzapine.
Metixene The therapeutic efficacy of Secretin human can be decreased when used in combination with Metixene.
Terfenadine The therapeutic efficacy of Secretin human can be decreased when used in combination with Terfenadine.
Buclizine The therapeutic efficacy of Secretin human can be decreased when used in combination with Buclizine.
Clozapine The therapeutic efficacy of Secretin human can be decreased when used in combination with Clozapine.
Doxylamine The therapeutic efficacy of Secretin human can be decreased when used in combination with Doxylamine.
Trihexyphenidyl The therapeutic efficacy of Secretin human can be decreased when used in combination with Trihexyphenidyl.
Oxyphencyclimine The therapeutic efficacy of Secretin human can be decreased when used in combination with Oxyphencyclimine.
Procyclidine The therapeutic efficacy of Secretin human can be decreased when used in combination with Procyclidine.
Profenamine The therapeutic efficacy of Secretin human can be decreased when used in combination with Profenamine.
Metocurine iodide The therapeutic efficacy of Secretin human can be decreased when used in combination with Metocurine iodide.
Secobarbital The therapeutic efficacy of Secretin human can be decreased when used in combination with Secobarbital.
Promazine The therapeutic efficacy of Secretin human can be decreased when used in combination with Promazine.
Hyoscyamine The therapeutic efficacy of Secretin human can be decreased when used in combination with Hyoscyamine.
Cyproheptadine The therapeutic efficacy of Secretin human can be decreased when used in combination with Cyproheptadine.
Imipramine The therapeutic efficacy of Secretin human can be decreased when used in combination with Imipramine.
Methscopolamine bromide The therapeutic efficacy of Secretin human can be decreased when used in combination with Methscopolamine bromide.
Metharbital The therapeutic efficacy of Secretin human can be decreased when used in combination with Metharbital.
Fluoxetine The therapeutic efficacy of Secretin human can be decreased when used in combination with Fluoxetine.
Chlorpromazine The therapeutic efficacy of Secretin human can be decreased when used in combination with Chlorpromazine.
Gallamine triethiodide The therapeutic efficacy of Secretin human can be decreased when used in combination with Gallamine triethiodide.
Darifenacin The therapeutic efficacy of Secretin human can be decreased when used in combination with Darifenacin.
Tridihexethyl The therapeutic efficacy of Secretin human can be decreased when used in combination with Tridihexethyl.
Triflupromazine The therapeutic efficacy of Secretin human can be decreased when used in combination with Triflupromazine.
Dextromethorphan The therapeutic efficacy of Secretin human can be decreased when used in combination with Dextromethorphan.
Anisotropine methylbromide The therapeutic efficacy of Secretin human can be decreased when used in combination with Anisotropine methylbromide.
Nortriptyline The therapeutic efficacy of Secretin human can be decreased when used in combination with Nortriptyline.
Amoxapine The therapeutic efficacy of Secretin human can be decreased when used in combination with Amoxapine.
Cisatracurium The therapeutic efficacy of Secretin human can be decreased when used in combination with Cisatracurium.
Atropine The therapeutic efficacy of Secretin human can be decreased when used in combination with Atropine.
Thiopental The therapeutic efficacy of Secretin human can be decreased when used in combination with Thiopental.
Nicardipine The therapeutic efficacy of Secretin human can be decreased when used in combination with Nicardipine.
Mecamylamine The therapeutic efficacy of Secretin human can be decreased when used in combination with Mecamylamine.
Pirenzepine The therapeutic efficacy of Secretin human can be decreased when used in combination with Pirenzepine.
Paroxetine The therapeutic efficacy of Secretin human can be decreased when used in combination with Paroxetine.
Procaine The therapeutic efficacy of Secretin human can be decreased when used in combination with Procaine.
Homatropine methylbromide The therapeutic efficacy of Secretin human can be decreased when used in combination with Homatropine methylbromide.
Rocuronium The therapeutic efficacy of Secretin human can be decreased when used in combination with Rocuronium.
Atracurium besylate The therapeutic efficacy of Secretin human can be decreased when used in combination with Atracurium besylate.
Scopolamine The therapeutic efficacy of Secretin human can be decreased when used in combination with Scopolamine.
Isoflurane The therapeutic efficacy of Secretin human can be decreased when used in combination with Isoflurane.
Benzquinamide The therapeutic efficacy of Secretin human can be decreased when used in combination with Benzquinamide.
Clidinium The therapeutic efficacy of Secretin human can be decreased when used in combination with Clidinium.
Propiomazine The therapeutic efficacy of Secretin human can be decreased when used in combination with Propiomazine.
Propantheline The therapeutic efficacy of Secretin human can be decreased when used in combination with Propantheline.
Primidone The therapeutic efficacy of Secretin human can be decreased when used in combination with Primidone.
Dicyclomine The therapeutic efficacy of Secretin human can be decreased when used in combination with Dicyclomine.
Biperiden The therapeutic efficacy of Secretin human can be decreased when used in combination with Biperiden.
Brompheniramine The therapeutic efficacy of Secretin human can be decreased when used in combination with Brompheniramine.
Methylphenobarbital The therapeutic efficacy of Secretin human can be decreased when used in combination with Methylphenobarbital.
Cocaine The therapeutic efficacy of Secretin human can be decreased when used in combination with Cocaine.
Quinidine The therapeutic efficacy of Secretin human can be decreased when used in combination with Quinidine.
Amantadine The therapeutic efficacy of Secretin human can be decreased when used in combination with Amantadine.
Maprotiline The therapeutic efficacy of Secretin human can be decreased when used in combination with Maprotiline.
Methantheline The therapeutic efficacy of Secretin human can be decreased when used in combination with Methantheline.
Hexafluronium The therapeutic efficacy of Secretin human can be decreased when used in combination with Hexafluronium.
Cycrimine The therapeutic efficacy of Secretin human can be decreased when used in combination with Cycrimine.
Desloratadine The therapeutic efficacy of Secretin human can be decreased when used in combination with Desloratadine.
Glycopyrronium The therapeutic efficacy of Secretin human can be decreased when used in combination with Glycopyrronium.
Tolterodine The therapeutic efficacy of Secretin human can be decreased when used in combination with Tolterodine.
Oxybutynin The therapeutic efficacy of Secretin human can be decreased when used in combination with Oxybutynin.
Promethazine The therapeutic efficacy of Secretin human can be decreased when used in combination with Promethazine.
Diphenhydramine The therapeutic efficacy of Secretin human can be decreased when used in combination with Diphenhydramine.
Pentolinium The therapeutic efficacy of Secretin human can be decreased when used in combination with Pentolinium.
Trimethaphan The therapeutic efficacy of Secretin human can be decreased when used in combination with Trimethaphan.
Doxacurium The therapeutic efficacy of Secretin human can be decreased when used in combination with Doxacurium.
Doxepin The therapeutic efficacy of Secretin human can be decreased when used in combination with Doxepin.
Flavoxate The therapeutic efficacy of Secretin human can be decreased when used in combination with Flavoxate.
Desipramine The therapeutic efficacy of Secretin human can be decreased when used in combination with Desipramine.
Orphenadrine The therapeutic efficacy of Secretin human can be decreased when used in combination with Orphenadrine.
Phenobarbital The therapeutic efficacy of Secretin human can be decreased when used in combination with Phenobarbital.
Escitalopram The therapeutic efficacy of Secretin human can be decreased when used in combination with Escitalopram.
Tubocurarine The therapeutic efficacy of Secretin human can be decreased when used in combination with Tubocurarine.
Quetiapine The therapeutic efficacy of Secretin human can be decreased when used in combination with Quetiapine.
Mivacurium The therapeutic efficacy of Secretin human can be decreased when used in combination with Mivacurium.
Levacetylmethadol The therapeutic efficacy of Secretin human can be decreased when used in combination with Levacetylmethadol.
Diphenidol The therapeutic efficacy of Secretin human can be decreased when used in combination with Diphenidol.
Aripiprazole The therapeutic efficacy of Secretin human can be decreased when used in combination with Aripiprazole.
Chlorprothixene The therapeutic efficacy of Secretin human can be decreased when used in combination with Chlorprothixene.
Fenoterol The therapeutic efficacy of Secretin human can be decreased when used in combination with Fenoterol.
Metocurine The therapeutic efficacy of Secretin human can be decreased when used in combination with Metocurine.
Pancuronium The therapeutic efficacy of Secretin human can be decreased when used in combination with Pancuronium.
Pipecuronium The therapeutic efficacy of Secretin human can be decreased when used in combination with Pipecuronium.
Vecuronium The therapeutic efficacy of Secretin human can be decreased when used in combination with Vecuronium.
Amobarbital The therapeutic efficacy of Secretin human can be decreased when used in combination with Amobarbital.
Aprobarbital The therapeutic efficacy of Secretin human can be decreased when used in combination with Aprobarbital.
Butobarbital The therapeutic efficacy of Secretin human can be decreased when used in combination with Butobarbital.

Target Protein

Secretin receptor SCTR

Referensi & Sumber

Artikel (PubMed)
  • PMID: 6168511
    Lankisch PG, Creutzfeldt W: Effect of synthetic and natural secretin on the function of the exocrine pancreas in man. Digestion. 1981;22(2):61-5. doi: 10.1159/000198596.
  • PMID: 24906040
    Sherman S, Freeman ML, Tarnasky PR, Wilcox CM, Kulkarni A, Aisen AM, Jacoby D, Kozarek RA: Administration of secretin (RG1068) increases the sensitivity of detection of duct abnormalities by magnetic resonance cholangiopancreatography in patients with pancreatitis. Gastroenterology. 2014 Sep;147(3):646-654.e2. doi: 10.1053/j.gastro.2014.05.035. Epub 2014 Jun 4.
  • PMID: 25332973
    Afroze S, Meng F, Jensen K, McDaniel K, Rahal K, Onori P, Gaudio E, Alpini G, Glaser SS: The physiological roles of secretin and its receptor. Ann Transl Med. 2013 Oct;1(3):29. doi: 10.3978/j.issn.2305-5839.2012.12.01.
  • PMID: 20944548
    Chu JY, Cheng CY, Lee VH, Chan YS, Chow BK: Secretin and body fluid homeostasis. Kidney Int. 2011 Feb;79(3):280-7. doi: 10.1038/ki.2010.397. Epub 2010 Oct 13.

Contoh Produk & Brand

Produk: 3 • International brands: 2
Produk
  • ChiRhoStim
    Injection, powder, lyophilized, for solution • 16 ug/8mL • Intravenous • US • Approved
  • ChiRhoStim 40
    Injection, powder, lyophilized, for solution • 40 ug/10mL • Intravenous • US • Approved
  • Secretin Inj 75unit/vial
    Powder, for solution • 75 unit / vial • Intravenous • Canada • Approved
International Brands
  • SecreFlo — Repligen Corp
  • Secremax — Repligen Corp

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul